Search Beyond News…

US-Rx Care urges employers to adopt rigorous contract-level scrutiny when selecting Pharmacy Benefit Managers

Executive summary: US-Rx Care issued a list of ten critical questions for employers to use when vetting transparent Pharmacy Benefit Managers (PBMs). It addresses the gap between PBM 'transparency' marketing and actual cost-containment results, focusing on fiduciary responsibility and audit rights.

Who is involved: US-Rx Care, employers, benefits providers, and Pharmacy Benefit Managers (PBMs).

Likely next: Increased pressure on PBMs to provide contract-level data and more sophisticated auditing by corporate benefits departments.

US-Rx Care has released a guidance framework for employers to evaluate PBM transparency beyond surface-level claims. The advisory emphasizes the necessity of testing for fiduciary duties, pricing structures, and data ownership at the contract level. This move follows a growing trend of stakeholders demanding more substantive accountability in pharmacy benefit management.

What's next — scenarios

Base: Increased scrutiny on contract terms (60%)

Employers demand more granular audit rights and data ownership clauses in PBM contracts.

Upside: Shift toward fiduciary-first PBM models (25%)

Market share shifts from traditional PBMs to transparent models that prioritize direct pass-through pricing.

Downside: Superficial compliance (15%)

PBMs implement 'transparency' features that do not materially impact the total cost of prescription drugs.

What to watch

Timeline

Analysis — what this means

Sectors affected

Regulatory implications

Historical parallels

Key entities

Sources

Related cases

Browse the full archive →